Burning Rock Biotech (NASDAQ:BNR) Issues Earnings Results

Burning Rock Biotech (NASDAQ:BNR) released its quarterly earnings data on Thursday. The company reported ($0.25) EPS for the quarter, FiscalAI reports. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%. The company had revenue of $19.84 million during the quarter.

Burning Rock Biotech Stock Up 12.0%

NASDAQ:BNR opened at $11.99 on Thursday. Burning Rock Biotech has a 1 year low of $6.79 and a 1 year high of $41.72. The stock has a 50-day moving average price of $9.90 and a two-hundred day moving average price of $14.00. The stock has a market cap of $126.13 million, a price-to-earnings ratio of -14.62 and a beta of 1.38. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings lowered Burning Rock Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Wall Street Zen lowered shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech has an average rating of “Sell”.

Insider Buying and Selling at Burning Rock Biotech

In other Burning Rock Biotech news, Director Yusheng Han acquired 250,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $2,000,000.00. Following the acquisition, the director directly owned 18,379,186 shares of the company’s stock, valued at approximately $147,033,488. This trade represents a 1.38% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders bought 706,650 shares of company stock worth $5,966,258. Insiders own 30.30% of the company’s stock.

Institutional Trading of Burning Rock Biotech

Large investors have recently bought and sold shares of the business. Prospera Financial Services Inc raised its holdings in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the period. Crcm LP boosted its holdings in shares of Burning Rock Biotech by 121.8% in the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after buying an additional 269,851 shares during the period. Marshall Wace LLP bought a new stake in shares of Burning Rock Biotech during the fourth quarter worth $220,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after acquiring an additional 4,290 shares during the period. 30.03% of the stock is owned by institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.